Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)

References

• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014;129:837-47
   PubMed Web of Science ®Google Scholar
• Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2016;13:501
   PubMed Web of Science ®Google Scholar
• Temu TM, Lane KA, Shen C, et al. Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. PLoS One 2017;12:e0185204
   PubMedGoogle Scholar
• Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37
   PubMed Web of Science ®Google Scholar
• WorldLifeExpectancy. World Health Rankings. Algeria: Strokes; 2017. Available at: http://www.worldlifeexpectancy.com/algeria-stroke
   Google Scholar
• World Health Organization. Health statistics and information systems. Disease burden and mortality estimates. Disease burden 2000–2015. Geneva: WHO; 2018. Available at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html
   Google Scholar
• Lamri L. Le système de sécurité sociale en Algérie: Approche économique. Algiers: Office des Publications Universitaires; 2004
   Google Scholar
• Le Heuzey JY, Marijon E, Lepillier A, et al. La fibrillation atriale: données démographiques. Réalités cardiologiques; 2010. Available at: http://www.realites-cardiologiques.com/wp-content/uploads/sites/2/2010/03/10.pdf
   Google Scholar
• Charlemagne A, Blacher J, Cohen A, et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis 2011;104:115-24
   PubMed Web of Science ®Google Scholar
• Office National des Statistiques. Alger; 2018. Available at: www.ons.dz/
   Google Scholar
• Ezekowitz MD, Eikelboom J, Oldgren J, et al. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace 2016;18:973-8
   PubMed Web of Science ®Google Scholar
• Huisman MV, Rothman KJ, Paquette M, et al. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. Am Heart J 2018;198:55-63
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-64
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemicembolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Chevalier J, Giroud M, de Pouvourville G. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation. Cerebrovasc Dis 2013;35:320-6
   PubMed Web of Science ®Google Scholar
• Chevalier J, Delaitre O, Hammès F, et al. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. Arch Cardiovasc Dis 2014;107:381-90
   PubMed Web of Science ®Google Scholar
• Sommerauer C, Schlender L, Krause M, et al. Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. BMC Geriatr 2017;17(Suppl 1):223
   PubMedGoogle Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC scientific document group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962
   PubMed Web of Science ®Google Scholar
• Bendriss L, Khatouri A. Ischemic stroke. Prevalence of cardiovascular causes documented by an extensive cardiovascular workup in 110 patients. Ann Cardiol Angeiol (Paris) 2012;61:252-6
   PubMedGoogle Scholar
• Gamra H, Murin J, Chiang CE, et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 2014;107:77-87
   PubMed Web of Science ®Google Scholar
• Chiang CE, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632-9
   PubMed Web of Science ®Google Scholar
• Steg PG, Alam S, Chiang C-E, et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart Br Card Soc 2012;98:195-201
   PubMedGoogle Scholar
• Ayed SD, Ayed RA, Tilouche N, et al. New onset of atrial fibrillation in a medical ICU: prevalence and risk factors. Int J Clin Med 2012;3:582
   Google Scholar
• Ouaha L, Drissi H, Sequali G, et al. Epidémiologie et traitement de la fibrillation auriculaire. Maroc Méd 2009;31:100-109
   Google Scholar
• Ragbaoui Y, Chehbouni C, Hammiri AE, et al. [Epidemiology of the relationship between atrial fibrillation and heart failure]. Pan Afr Med J 2017;26:116
   PubMed Web of Science ®Google Scholar
• Benamer HTS, Grosset D. Stroke in Arab countries: a systematic literature review. J Neurol Sci 2009;284:18-23
   PubMed Web of Science ®Google Scholar
• Chiang CE, Naditch-Brûlé L, Brette S, et al. Atrial fibrillation management strategies in routine clinical practice: insights from the International RealiseAF Survey. PLoS One 2016;11(1):e0147536
   Web of Science ®Google Scholar
• Murin J, Naditch-Brûlé L, Brette S, et al. Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One 2014;9(1):e86443
   PubMed Web of Science ®Google Scholar
• Ziane. Atrial fibrillation in the world and in Morrocco. Djerba, Morocco: Congrès Maghrébin de Cardiologie; 2017
   Google Scholar
• Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99:3028-35
   Google Scholar
• Lamri L, Latek A. Priorités de santé en Algérie – Rapport pour la Banque Mondial [Health priorities in Algeria – Report for the Global Bank]. Algiers: Institut National de Santé Publique, 1998.
   Google Scholar
• Lamri L. Coût et management du diabète en Algérie. La Presse Médicale; 2017. Available at: http://www.pressemedicale.com/news/cout-et-management-du-diabete-en-algerie
   Google Scholar
• University of Sherbrooke. Perspective Monde. Dépenses en santé par habitant ($US courant), Algérie. 2016. Available at: http://perspective.usherbrooke.ca/bilan/servlet/BMTendanceStatPays?codeTheme=3&codeStat=SH.XPD.PCAP&codePays=FRA&optionsPeriodes=Aucune&codeTheme2=3&codeStat2=SH.XPD.PCAP&codePays2=DZA&optionsDetPeriodes=avecNomP
   Google Scholar
• Aoudia Y, Kongnakorn T, Merinopoulou E, et al. Cost-effectiveness of apixaban for stroke prevention in patients with atrial fibrillation in Algeria. JHEOR 2017;5:39-54
   Google Scholar
• Briere JB, Bowrin K, Wood R, et al. The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective. J Med Econ 2017;20:266-72
   PubMed Web of Science ®Google Scholar
• Briere JB, Bowrin K, Wood R, et al. The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective. J Med Econ 2017;20:599-605
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Dalby LW, Täckström T, et al. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res 2017;17:714
   PubMed Web of Science ®Google Scholar
• Jakobsen M, Kolodziejczyk C, Klausen Fredslund E, et al. Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study. BMC Health Serv Res 2017;17:398
   PubMed Web of Science ®Google Scholar
• Santos JV, Pereira J, Pinto R, et al. Atrial fibrillation as an ischemic stroke clinical and economic burden modifier: a 15-year nationwide study. Value Health 2017;20:1083-91
   PubMed Web of Science ®Google Scholar